The rise of rational strategies in nanomedicine development, such as high-throughput
methods and computer-aided techniques, has led to a shift in the design and discovery …

Targeted protein degradation (TPD) has emerged as a revolutionary paradigm in drug
discovery and development, offering a promising avenue to tackle challenging therapeutic …

PROteolysis TArgeting Chimeras (PROTACs), as a recently identified technique in the field
of new drug development, provide new concepts for disease treatment and are expected to …

Proteolysis targeting chimeras (PROTACs) represent a transformative class of therapeutic
agents that leverage the intrinsic protein degradation machinery to modulate the hemostasis …

Microvascular dysfunction following myocardial infarction exacerbates coronary flow
obstruction and impairs the preservation of ventricular function. The apelinergic system …

Abstract Proteolysis Targeting Chimeras (PROTACs) represent a significant advancement in
therapeutic drug development by leveraging the ubiquitin‐proteasome system to enable …

Proteolysis targeting chimeras (PROTACs) can use the intrinsic protein degradation system
in cells to degrade pathogenic target proteins, and are currently a revolutionary frontier of …

Cancer stem cells (CSCs) with hyperactivated signal transducer and activator of
transcription 3 (STAT3) are a major driver of hepatocellular carcinoma (HCC). Herein, we …

Abnormal activation of EGFR is often associated with various malignant tumors, making it an
important target for antitumor therapy. However, traditional targeted inhibitors have several …

Methylation of adenine N6 (m6A) is the most frequent RNA modification. On mRNA, it is
catalyzed by the METTL3–14 heterodimer complex, which plays a key role in acute myeloid …